Stockreport

How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions [Yahoo! Finance]

Pulmonx Corporation  (LUNG) 
US:NASDAQ Investor Relations: investor.prolunginc.com/investor-relations
PDF Pulmonx's fair value estimate has been reset from US$5.75 to about US$5.17 per share, putting a fresh spotlight on what analysts are building into their models. Recent [Read more]